AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
Shimony S, Murdock H, Keating J, Reilly C, Tsai H, Gibson C, Faderl S, Wagner T, Dronamraju N, Lin T, Ritchie E, Prebet T, Cortes J, Uy G, Lancet J, Neuberg D, Stone R, Lindsley R. AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial. Blood 2024, 144: 60-60. DOI: 10.1182/blood-2024-200413.Peer-Reviewed Original ResearchAcute myeloid leukemiaTherapy-related AMLGermline DDX41 mutationsCPX-351Platelet recovery timeTP53 mutationsOverall survivalDDX41 mutationsTreatment armsCR/CRi rateMedian OSS-AMLPrognosis of t-AMLTherapy-related acute myeloid leukemiaAnalyzed outcomesSecondary acute myeloid leukemiaAML classificationSubsets of acute myeloid leukemiaConcurrent TP53 mutationImproved overall survivalHistory of MDSDe novoPhase 3 trialFavorable treatment outcomesTargeted mutation analysis